Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Shares gained 18.1% over 21 trading days and 5.8% over the latest five sessions, closing at the period high. Better-than-expected Q2 results, raised organic-growth and EPS guidance, improving bioprocessing orders, and positive free cash flow support continuation potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profitability Recovery ⢠Strong Cash Flow ⢠Elevated Leverage AVTR's profitability and cash flow have improved, but high leverage, limited cash coverage, and intangible-heavy assets keep the risk profile elevated.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Resistance test ⢠Recent pullback Support Level: $15.40â$15.45 Resistance Level: $15.85â$15.90 AVTR remains bullish over the last month, with support at $15.40â$15.45 and a sustained break above $15.90 needed to resume momentum.
Sentiment & News
Key News Insights: ⢠Raised outlook ⢠BMP weakness ⢠APAC expansion Avantor's improving results, raised outlook, institutional buying, and APAC bioprocessing expansion support recovery momentum, though BMP weakness and margin pressure remain key risks.
AI Summary
Avantor's recovery is increasingly credible on restored profitability and strong free cash flow, but with organic revenue still negative and leverage high, investors should treat AVTR's recovery-priced valuation as justified only if BMP/VWR demand turns sustainably positive and supports gradual deleveraging.
Description
Avantor, Inc. is a global supplier to biopharma, healthcare, education, government, advanced technologies and applied materials sectors, operating across the Americas, Europe, Asia, the Middle East and Africa. The company provides a broad range of laboratory and production inputsâincluding chemicals, consumables, instrumentation and critical environment equipmentâalongside onsite and development services, procurement support and scale-up capabilities for biopharmaceutical manufacturing. Founded in 1904, Avantor is headquartered in Radnor, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 16 | Sep 23 | AVTR | Avantor, Inc. | Shares gained 18.1% over 21 trading days and 5.8% over the latest five sessions, closing at the period high. Better-than-expected Q2 results, raised organic-growth and EPS guidance, improving bioprocessing orders, and positive free cash flow support continuation potential. | Closed | -5.5% |
| Jul 29 | Aug 5 | AVTR | Avantor, Inc. | Q2 release on 2026-07-29 showed adjusted EPS of $0.21 beating $0.19 estimates, healthy cash flow, and raised FY 2026 organic revenue growth and adjusted EPS guidance. Shares are up about 43% over 21 trading days, confirming strong momentum. | Closed | -7.1% |